Navigation Links
Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
Date:3/25/2011

CAMBRIDGE, Mass., March 25, 2011 /PRNewswire/ -- Mersana Therapeutics today announced  the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer.  The study will be carried out in 10 clinical centers in the US.  The Phase 1b follows the successful completion of a 74-patient Phase 1 clinical trial, which demonstrated high and prolonged plasma levels of XMT-1001 active release products and a safety profile free of the toxicities normally associated with topoisomerase 1 inhibitors, such as hemorrhagic cystitis and diarrhea.  Additionally, XMT-1001 showed promising evidence of clinical activity, including tumor shrinkage and prolonged stable disease, in a heavily pre-treated patient population.  

"Our recently completed Phase 1 study has confirmed the potential efficacy and safety advantages of the unique design of our lead Fleximer conjugate, XMT-1001," said Nick Bacopoulos, Ph.D., Chief Executive Officer of Mersana.  "We believe we are now able to fully explore the broad anti-tumor potential of XMT-1001 and are excited to initiate recruitment in our Phase 1b program."

"Our clinical experience with XMT-1001 to date suggests that it can be safely given up to doses limited by its mechanism, and thus may be useful in maximizing the therapeutic potential of its class.  The potential benefit of this agent in second-line gastric cancer and in second-/third-line non-small cell lung cancer, areas of great medical need, is well worth investigating," said Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clin
'/>"/>

SOURCE Mersana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
2. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/rf4hfn/global ) has ... Diseases Market 2015-2019" report to their offering. ... grow at a CAGR of 4.77% over the ... present scenario and the growth prospects of the ... To calculate the market size, the report considers ...
(Date:6/3/2015)... BOSTON , June 3, 2015 PillPack, ... has completed a $50 million round of financing led ... Menlo Ventures, and Sherpa Ventures. The capital will be ... world-class team, and build retail pharmacies in US markets. ... and launched a better, simpler pharmacy experience that folks ...
(Date:6/3/2015)... June 3, 2015  Armetheon, Inc., a specialty ... cardiovascular diseases, today announced that Sanjay Kakkar ... Executive Officer, effective immediately. Dr. Kakkar brings more ... enterprises, with a successful track record in advancing ... With expertise that includes the development of novel ...
Breaking Medicine Technology:Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4
... 2007--Treatment data from,Synovate Healthcare’s European Oncology Monitor reveals ... could become eligible,for a breast cancer treatment showing ... subject of a recent study detailed,in the online ... rates were shown in patients who had switched ...
... Findings Show Survival Improvement with Lower Doses ... and other,Drugs in Newly Diagnosed Myeloma -, ... -- The,International Myeloma Foundation (IMF) - supporting ... myeloma patients,families, researchers and physicians - today ...
Cached Medicine Technology:Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 2Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 3The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients 2The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients 3
(Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
(Date:6/3/2015)... Raleigh, NC (PRWEB) June 03, 2015 ... on two biomarkers for mesothelioma and say the tried-and-true ... has just posted an article on the research. ... in the University’s National Center for Asbestos Related Diseases ... false positive results, it is still preferable to fibulin-3 ...
(Date:6/3/2015)... TN (PRWEB) June 03, 2015 According ... Inquisitr police officers intercepted fake oxycodone pills which ... pills were doctored to look legitimate, and even sported ... officers are warning those consuming 30 mg oxycodone to ... the pills online or buy them illegally on the ...
(Date:6/3/2015)... June 03, 2015 Fourroux Prosthetics, located ... GA will celebrate its grand opening with a ribbon ... first prosthetic center of its kind in the area, ... unmatched care and outcomes through use of patented advanced ... & CEO of Fourroux Prosthetics, states, “Our goal has ...
(Date:6/3/2015)... DailyEndorphin is pleased to announce the launch ... this highly configurable new offering, DE's annual clients may ... of its wellness programming for the entire year as ... this new module, annual clients may also do the ... surveys, (3) Continually report on participant progress towards the ...
Breaking Medicine News(10 mins):Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2
... Alan Mozes HealthDay Reporter , TUESDAY, May 15 ... silver bullet when it comes to symptom relief for acute ... of six prior studies found that the sprays confer only ... for three weeks at relatively high doses. The disappointing ...
... May 15 (HealthDay News) -- Should Americans be able to buy ... they,re infected with the virus that causes AIDS? , , A ... question Tuesday, and the answer the panel arrives at could pave ... advisory panel recommendations are not binding, but they are often followed ...
... KNOX, Ky., May 15, 2012 The U.S. Army Medical ... to Mastership in the American College of Physicians (MACP). Only ... eminence through their contributions to the field of internal medicine ... or volunteerism, were awarded a Mastership in 2012. One of ...
... Child,s Age and Severity of Gait Abnormality ,Most ... 2. And while some toe walkingwhere a child primarily walks ... the heel to the groundis common, persistent toe walking beyond ... article, "Idiopathic Toe Walking," outlines the appropriate steps for effectively ...
... Center at HakensackUMC, one of the nation,s top 50 cancer ... year,s program, titled New Horizons in Neuro-Oncology- Innovations in the ... the most important advancements and innovations for the treatment of ... on Friday, May 18 from 8:00am to 1:00pm. ...
... a way to save money while having little effect on ... study. Researchers say that 57.6 percent of patients ... schizophrenia or bipolar disorder, the conditions for which the drugs ... is not FDA-approved is called off-label use. "Given ...
Cached Medicine News:Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 3Health News:FDA Panel to Consider At-Home HIV Test 2Health News:FDA Panel to Consider At-Home HIV Test 3Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 2Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 3Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 4Health News:Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights 2Health News:John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium 2Health News:Reducing off-label use of antipsychotic medications may save money 2Health News:Reducing off-label use of antipsychotic medications may save money 3
Fortitude as a unique complement to the spinal concepts family of products....
... implant made of radiolucent carbon fiber ... has a modulus of elasticity approximating ... is an implant that meets the ... while optimizing the fusion environment through ...
... Spinal Implant system. Material that has a ... bone. The result is an implant that ... support, while optimizing the fusion environment through ... anatomic design with 5 and 10 degrees ...
Caspar cervical retractor (lamina spreader), counter-retractor complete with 5 blades and forceps. Height: max. 165 mm, Maximal spread: 85 mm...
Medicine Products: